MarketLens

Is Ionis Pharmaceuticals Poised for a Breakthrough with Tryngolza

5 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Rhythm Pharmaceuticals Poised for a Breakthrough in Hypothalamic Obesity

5 months ago

Ionis Pharmaceuticals: A Director's $1 Million Bet Against the Bear

2 weeks ago

Is EcoSolutions Waste Poised for a Biofuel Breakthrough

5 months ago

Is Protagenic Therapeutics (PTIX) Poised for a Breakthrough in Neuropsychiatric Treatment

3 months ago

Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?

Ionis shares plunged 30% after Q2 revenue fell, though last year included a large one-time payment. Other earnings-report signs of trouble added to the decline, pressuring the biotech's valuation.

IONS

Stock News•1 week ago

Ionis Pharmaceuticals Director Hayden Buys $1.1 Million Shares. What Does This Mean for Investors?

Ionis Pharmaceuticals director Hayden bought 20,000 shares for ~$1.1 million, raising his direct and indirect holdings by 34%, signaling insider confidence.

IONS

Stock News•2 months ago

Ionis Pharmaceuticals, Inc. (IONS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Ionis Pharmaceuticals presented at the Goldman Sachs healthcare conference. The presentation likely covered pipeline updates and strategic outlook.

IONS

Stock News•2 months ago

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals is entering a broader commercial and late-stage development phase, highlighted by an upcoming regulatory decision for TRYNGOLZA and five Phase 3 clinical readouts. The company ai...

IONS